Clinical Trials Logo

Ulcerative Colitis clinical trials

View clinical trials related to Ulcerative Colitis.

Filter by:

NCT ID: NCT02962245 Not yet recruiting - Ulcerative Colitis Clinical Trials

Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis

Start date: November 2016
Phase: Phase 4
Study type: Interventional

The research aim to find out whether berberine can reduce the annual recurrence rate of ulcerative colitis in remission. A total of 238 patients with ulcerative colitis in remission will be randomly divided into two groups.One will receive regular treatment,and the other group will receive extra oral berberine 300 mg three times daily for a year. The end of the study for every patient is disease recurrence(Mayo Clinic score of 3 points or more ). The primary analysis is annual recurrence rate, and both endoscopy and Mayo Clinic disease activity index scores at the baseline and final assessments.

NCT ID: NCT02958865 Not yet recruiting - Ulcerative Colitis Clinical Trials

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

Start date: December 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis.

NCT ID: NCT02954159 Not yet recruiting - Ulcerative Colitis Clinical Trials

Induction of Response and Remission of Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in Patients With Ulcerative Colitis

(COVET)
Start date: February 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess if a combination therapy of tacrolimus and vedolizumab is superior to vedolizumab monotherapy for induction of remission in moderate to severe UC, and its effect on long and short-term outcomes including colectomy rate. Secondary aim of this study is to assess the safety of tacrolimus as an induction agent in patients with UC when used in combination with vedolizumab.

NCT ID: NCT02931162 Not yet recruiting - Ulcerative Colitis Clinical Trials

The Effects of Moxibustion on Ulcerative Colitis

Start date: October 2016
Phase: N/A
Study type: Interventional

To investigate the mechanism and effects of moxibustion on patients with ulcerative colitis.

NCT ID: NCT02925338 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life

ReFLECT
Start date: October 2016
Phase: N/A
Study type: Observational

National, prospective, multicentre observational study designed for eligible patients treated with Inflectra. Its objectives are to describe under real conditions of use, the profile of patients treated with Inflectra and the response to treatment.

NCT ID: NCT02922881 Not yet recruiting - Ulcerative Colitis Clinical Trials

Microbiota-targeted Diet for Pediatric UC

UCD
Start date: October 2016
Phase: N/A
Study type: Interventional

Ulcerative colitis is a chronic inflammatory disease primarily involving the colon and has long been considered to be due to a dysregulated immune response targeting the colon, and involves unknown environmental factors. Currently, no effective therapy targets the microbiota or its interaction with the colonic epithelium. Diet has a significant impact on the composition of the microbiota; however, no dietary intervention to date has proven effective for induction of remission. The primary objective of this study is to determine whether the Ulcerative Colitis Diet (UCD) can induce remission or response in pediatric UC patients with active mild to moderate UC on a stable medication.

NCT ID: NCT02921555 Not yet recruiting - Ulcerative Colitis Clinical Trials

Endovenous Corticosteroid Pulses in Moderate Ulcerative Colitis

CECUM
Start date: October 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the efficacy of high-dose corticosteroid pulses added to conventional oral corticosteroid course for moderate flares of ulcerative colitis.

NCT ID: NCT02914717 Not yet recruiting - Ulcerative Colitis Clinical Trials

The Belgian SMART Study Evaluating the Use of Golimumab for Ulcerative Colitis

BE SMART
Start date: September 2016
Phase: N/A
Study type: Observational

Ulcerative colitis (UC) is a chronic inflammatory condition causing continuous mucosal inflammation of the colon, which is accompanied by episodes of bloody diarrhoea and abdominal pain. Both infliximab and adalimumab have been used with success for moderate-to-severe UC refractory to conventional therapy. More recently, golimumab, another anti-TNF antibody, has been added to the treatment armamentarium. In the multi-centre, double-blind, placebo-controlled PURSUIT trial, patients with moderate-to-severe UC randomized to induction therapy with golimumab (200-100 mg, or 100-50 mg at week 0 and 2) achieved clinical response, clinical remission and mucosal healing more frequent than patients randomized to placebo. In the PURSUIT maintenance trial, patients randomized to golimumab every four weeks (100 or 50 mg) maintained clinical response through week 54 significantly more often than patients randomized to placebo. Data on the use of golimumab in daily clinical practice are unavailable. The aim of the retrospective Belgian multi-centre BE-SMART trial is to evaluate the mid-term outcome of golimumab in patients with moderate-to-severe colitis. The primary endpoint will be steroid-free golimumab continuation at week 26. Secondary endpoints will include (steroid-free) clinical remission, (steroid-free) clinical response, (steroid-free) mucosal healing, (steroid-free) complete mucosal healing hospitalization-free survival, and colectomy-free survival.

NCT ID: NCT02914535 Not yet recruiting - Ulcerative Colitis Clinical Trials

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

Start date: January 2017
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior Gilead-sponsored filgotinib treatment study in ulcerative colitis (UC).

NCT ID: NCT02914522 Recruiting - Ulcerative Colitis Clinical Trials

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis

Start date: October 2016
Phase: Phase 3
Study type: Interventional

The primary objectives of this study are to evaluate the safety and efficacy of filgotinib in the induction and maintenance treatment of moderately to severely active ulcerative colitis (UC) in participants who are biologic-naive and biologic-experienced. Participants who complete the study, or do not meet protocol response or remission criteria at Week 10 will have the option to enter a separate, long-term extension (LTE) study (Gilead Study GS-US-418-3899).